Osteopontin Mediates Cetuximab Resistance via the MAPK Pathway in NSCLC Cells

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.2133226742998
   PubMed Web of Science ®Google Scholar
• Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31(8):1039–1049. doi:10.1200/JCO.2012.45.375323401433
   PubMed Web of Science ®Google Scholar
• Coate LE, Shepherd FA. Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. Ther Adv Med Oncol. 2011;3(3):139–157. doi:10.1177/175883401139930621904577
   PubMedGoogle Scholar
• Zhan J, Wang P, Li S, et al. HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients. Theranostics. 2019;9(7):2084–2099. doi:10.7150/thno.2946331037158
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–578. doi:10.1056/NEJMoa05342216467544
   PubMed Web of Science ®Google Scholar
• Rosenthal DI, Harari PM, Giralt J, et al. Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase III registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab. J Clin Oncol. 2016;34(12):1300–1308. doi:10.1200/JCO.2015.62.597026712222
   PubMed Web of Science ®Google Scholar
• Borghaei H, Langer CJ, Millenson M, et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008;3(11):1286–1292. doi:10.1097/JTO.0b013e318189f50e18978564
   PubMed Web of Science ®Google Scholar
• Moran T. Is more the better?-Cetuximab in non-small cell lung cancer patients. Transl Lung Cancer Res. 2018;7(Suppl 3):S195–S197. doi:10.21037/tlcr.2018.04.1430393599
   PubMedGoogle Scholar
• Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010;103(6):861–869. doi:10.1038/sj.bjc.660583420823889
   PubMed Web of Science ®Google Scholar
• Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14(8):2037–2044. doi:10.1111/jcmm.2010.14.issue-820597997
   PubMed Web of Science ®Google Scholar
• Bandopadhyay M, Bulbule A, Butti R, et al. Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets. 2014;18(8):883–895. doi:10.1517/14728222.2014.92544724899149
   PubMed Web of Science ®Google Scholar
• Pang H, Cai L, Yang Y, Chen X, Sui G, Zhao C. Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. Cancer Biother Radiopharm. 2011;26(2):165–173. doi:10.1089/cbr.2010.083821539449
   PubMed Web of Science ®Google Scholar
• Hsieh IS, Huang WH, Liou HC, Chuang WJ, Yang RS, Fu WM. Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol Pharmacol. 2013;83(5):968–977. doi:10.1124/mol.112.08233923434829
   PubMed Web of Science ®Google Scholar
• Donati V, Boldrini L, Dell’Omodarme M, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res. 2005;11(18):6459–6465. doi:10.1158/1078-0432.CCR-05-054116166420
   PubMed Web of Science ®Google Scholar
• Ouyang X, Huang Y, Jin X, et al. Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer. Onco Targets Ther. 2018;11:5933–5941. doi:10.2147/OTT30275702
   PubMed Web of Science ®Google Scholar
• Hu Z, Lin D, Yuan J, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res. 2005;11(13):4646–4652. doi:10.1158/1078-0432.CCR-04-201316000556
   PubMed Web of Science ®Google Scholar
• Wang M, Han J, Marcar L, et al. Radiation resistance in KRAS-mutated lung cancer is enabled by stem-like properties mediated by an osteopontin-EGFR pathway. Cancer Res. 2017;77(8):2018–2028. doi:10.1158/0008-5472.CAN-16-080828202526
   PubMed Web of Science ®Google Scholar
• Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47. doi:10.1038/nrc70411902584
   PubMed Web of Science ®Google Scholar
• Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001;61(13):5090–5101.11431346
   PubMed Web of Science ®Google Scholar
• Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem. 2006;281(36):25903–25914. doi:10.1074/jbc.M60341420016847054
   PubMed Web of Science ®Google Scholar
• Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98(24):13790–13795. doi:10.1073/pnas.19150299811707567
   PubMed Web of Science ®Google Scholar
• Hou J, Aerts J, den Hamer B, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 2010;5(4):e10312. doi:10.1371/journal.pone.001031220421987
   PubMed Web of Science ®Google Scholar
• Landi MT, Dracheva T, Rotunno M, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One. 2008;3(2):e1651. doi:10.1371/journal.pone.000165118297132
   PubMed Web of Science ®Google Scholar
• Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012;22(7):1197–1211. doi:10.1101/gr.132662.11122613842
   PubMed Web of Science ®Google Scholar
• Su LJ, Chang CW, Wu YC, et al. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics. 2007;8:140. doi:10.1186/1471-2164-8-14017540040
   PubMed Web of Science ®Google Scholar
• Wei CH, Wu G, Cai Q, et al. MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway. J Hematol Oncol. 2017;10(1):125. doi:10.1186/s13045-017-0493-028629431
   PubMedGoogle Scholar
• Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2012;10(10):1236–1271. doi:10.6004/jnccn.2012.013023054877
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17(12):725–737. doi:10.1038/nrc.2017.8729077690
   PubMed Web of Science ®Google Scholar
• Herbst RS, Kelly K, Chansky K, et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010;28(31):4747–4754. doi:10.1200/JCO.2009.27.935620921467
   PubMed Web of Science ®Google Scholar
• Kim ES, Moon J, Herbst RS, et al. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013;8(12):1519–1528. doi:10.1097/JTO.000000000000000924189513
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010;28(6):911–917. doi:10.1200/JCO.2009.21.961820100966
   PubMed Web of Science ®Google Scholar
• Salama JK, Vokes EE. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol. 2013;31(8):1029–1038. doi:10.1200/JCO.2012.44.506423401449
   PubMed Web of Science ®Google Scholar
• Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10(1 Pt 1):184–190. doi:10.1158/1078-0432.CCR-1405-214734468
   PubMed Web of Science ®Google Scholar
• Ortiz-Martinez F, Perez-Balaguer A, Ciprian D, et al. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. Hum Pathol. 2014;45(3):504–512. doi:10.1016/j.humpath.2013.10.01524440093
   PubMed Web of Science ®Google Scholar
• Hao C, Wang Z, Gu Y, Jiang WG, Cheng S. Prognostic value of osteopontin splice variant-c expression in breast cancers: a meta-analysis. Biomed Res Int. 2016;2016:7310694. doi:10.1155/2016/731069427462610
   PubMed Web of Science ®Google Scholar
• Sun BS, You J, Li Y, Zhang ZF, Wang CL. Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis. Chin Med J (Engl). 2013;126(9):1683–1688.23652051
   PubMed Web of Science ®Google Scholar
• Gu T, Ohashi R, Cui R, et al. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer. 2009;66(2):176–183. doi:10.1016/j.lungcan.2009.02.00419285749
   PubMed Web of Science ®Google Scholar
• Herner A, Sauliunaite D, Michalski CW, et al. Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. Int J Cancer. 2011;129(10):2349–2359. doi:10.1002/ijc.v129.1021207374
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang L, Liao R. Long non-coding RNA SDPR-AS affects the development of non-small cell lung cancer by regulating SDPR through p38 MAPK/ERK signals. Artif Cells Nanomed Biotechnol. 2019;47(1):3172–3179. doi:10.1080/21691401.2019.164290431352804
   PubMed Web of Science ®Google Scholar
• Robertson BW, Bonsal L, Chellaiah MA. Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol Cancer. 2010;9:260. doi:10.1186/1476-4598-9-26020868520
   PubMed Web of Science ®Google Scholar
• Chen YJ, Wei YY, Chen HT, et al. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol. 2009;221(1):98–108. doi:10.1002/jcp.2183519475568
   PubMed Web of Science ®Google Scholar
• Kato A, Okura T, Hamada C, et al. Cell stress induces upregulation of osteopontin via the ERK pathway in type II alveolar epithelial cells. PLoS One. 2014;9(6):e100106. doi:10.1371/journal.pone.010010624963635
   PubMed Web of Science ®Google Scholar